DigiM Solution receives FDA contract for microstructure imaging study

DigiM Solution LLC, a provider of microstructure characterization and optimization solutions and software, has received a contract from the Office of Generic Drugs of the U.S. Food and Drug Administration (FDA). The project will address the correlation of microstructures of complex long-acting drug products with their in vitro release characteristics.

The study is a joint collaboration between DigiM and the laboratory of Prof. Diane J. Burgess at the University of Connecticut in Storrs, Connecticut.

Extended-release drug products are patient centric and offer important advantages when compared with more commonly used immediate-release formulations. These advantages include less dose frequency, improved drug efficacy, and decreased risk of adverse effects.

In vitro release testing of complex long-acting products is essential in furthering product development, batch manufacturing, in vitro/in vivo correlations, bioequivalence studies for generics, and determination of shelf-life; however, the complexity of these formulations makes typical in vitro characterization techniques both time and cost prohibitive.

With this joint effort, DigiM will develop a framework for accelerated release evaluation using high-resolution microstructure imaging, image processing, and image-based release simulation of monolithic extended-release drug products, a representative delivery system with wide industrial popularity. The Burgess Laboratory will design and manufacture drug product samples, as well as conduct physical characterization and in vitro release testing independently to validate DigiM’s model.

The microstructures of controlled release dosage forms have great impact on active pharmaceutical ingredient release and are complex in nature. For example, a transport-controlling microporous system often has pore throats as small as a few tens of nanometers to ensure sustained release over weeks. Sophisticated understanding of the microstructures of the controlled release forms will enhance the predictability of in vitro/in vivo models. So far, there has been very limited investigation of the relationship between microstructures and active pharmaceutical ingredient release. The nature of these long-acting drugs has made bioequivalence studies very challenging in general. The unique synergy between the skill sets of DigiM and UConn teams offer a great opportunity to establish a potentially efficient platform to facilitate development of generic long-acting drugs.”

Dr. Yan Wang, Project Officer of the FDA

We are privileged to have the opportunity to work on this challenge. Through high resolution 3D micro-imaging, API domains and porosity can be visualized and quantified. DigiM’s patent pending technology in combining drug microstructure with release profile prediction model has the potential to produce a release profile in a matter of hours, which will considerably accelerate the evaluation time of formulation and processing parameters in long acting drug development.”

Dr. Shawn Zhang, Founder and CEO of DigiM

Prof. Burgess further commented:

The study will determine the relationship between the drug microstructure (including microporosity) and in vitro release characteristics. The effect of manufacturing conditions on the release properties and physicochemical characteristics will also be examined. The project seeks to establish quantitative microstructure imaging analysis as a supplemental modeling tool to current in vitro approaches. Establishing their correlation and use of microstructure imaging may ultimately be a significant asset in developing alternative novel approaches for assessing bioequivalence.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    DigiM Solution LLC. (2019, December 13). DigiM Solution receives FDA contract for microstructure imaging study. News-Medical. Retrieved on January 20, 2020 from https://www.news-medical.net/news/20191213/DigiM-Solution-receives-FDA-contract-for-microstructure-imaging-study.aspx.

  • MLA

    DigiM Solution LLC. "DigiM Solution receives FDA contract for microstructure imaging study". News-Medical. 20 January 2020. <https://www.news-medical.net/news/20191213/DigiM-Solution-receives-FDA-contract-for-microstructure-imaging-study.aspx>.

  • Chicago

    DigiM Solution LLC. "DigiM Solution receives FDA contract for microstructure imaging study". News-Medical. https://www.news-medical.net/news/20191213/DigiM-Solution-receives-FDA-contract-for-microstructure-imaging-study.aspx. (accessed January 20, 2020).

  • Harvard

    DigiM Solution LLC. 2019. DigiM Solution receives FDA contract for microstructure imaging study. News-Medical, viewed 20 January 2020, https://www.news-medical.net/news/20191213/DigiM-Solution-receives-FDA-contract-for-microstructure-imaging-study.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post